Bisphosphonate stimulation of osteoblasts and osteoblastic metastasis as a mechanism of hypocalcaemia

Medical Hypotheses

Volumn 78, Issue 3, 2012, Pages 377-379

  Ho, Joon Wee ^a  

^a NOTTINGHAM CITY HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; ANTIANDROGEN; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; ETOPOSIDE; IBANDRONIC ACID; RISEDRONIC ACID; ZOLEDRONIC ACID;

ANTIANDROGEN THERAPY; ANTINEOPLASTIC ACTIVITY; ARTICLE; BONE METASTASIS; BONE MINERALIZATION; BONE TURNOVER; CALCIUM BLOOD LEVEL; CALCIUM TRANSPORT; CANCER PATIENT; CELL ACTIVITY; CELL MATURATION; CELL PROLIFERATION; CELL STIMULATION; DRUG EFFECT; DRUG EFFICACY; HUMAN; HYPOCALCEMIA; INCIDENCE; LOW DRUG DOSE; OSTEOBLAST; OSTEOCLAST; PROSTATE CANCER; RISK FACTOR;

BONE NEOPLASMS; CALCIFICATION, PHYSIOLOGIC; DIPHOSPHONATES; HUMANS; HYPOCALCEMIA; MALE; MODELS, BIOLOGICAL; OSTEOBLASTS; PROSTATIC NEOPLASMS;

EID: 84856471491     PISSN: 03069877     EISSN: 15322777     Source Type: Journal    
DOI: 10.1016/j.mehy.2011.12.002     Document Type: Article

References (19)

1. Cancer Research UK. Prostate cancer statistics - key facts [Online] November 2010. [cited 16.01.2011]. http://info.cancerresearchuk.org.
2. Bubendorf L., Schoepfer A., Wagner U., Sauter G., Moch H., Willi N., et al. Metastatic patterns of prostate cancer; an autopsy study of 1589 patients. Hum Pathol 2000, 31(5):;578-583.
3. Saad F., Gleason D.M., Murray R., Tchekmedyian S., Venner P., Lacombe L., et al. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst 2002, 94(19):1458-1468.
4. Novartis. Zometa - Summary of Product Characteristics. [Online] 2010 http://www.zometa.com/.
5. Miho Hanamura, Iwamoto Takuya, Soga Norihito, Sugimura Yoshiki, Okuda Masahiro Risk factors contributing to the development of hypocalcemia after zoledronic acid administration in patients with bone metastases of solid tumour. Biol Pharm Bull 2010, 33(4):721-724.
6. Zuradelli M., Masci G., Biancafiore G., et al. Oncologist 2009, 14:548-556.
7. Chennuru S., Koduri J., Baumann M.A. Risk factors for symptomatic hypocalcaemia complicating treatment with zoledronic acid. Intern Med J 2008, 38:635-637.
8. Lim S.C., Tan C.E., Aw T.C., Khoo D. A man with osteoblastic metastasis and hypocalcaemia. Singapore Med J 2000, 41(2):74-76.
9. Fokkema M.I., de Heide L.J.M., van Schelven W.D., Hamdy N.A.T. Severe hypocalcaemia associated with extensive osteoblastic metastases in a patient with prostate cancer. Neth J Med 2005, 63(1):34-37.
10. Szentirmai M., Constantinou C., Rainey J., Loewenstein J. Hypocalcaemia due to avid calcium uptake by osteoblastic metastases of prostate cancer. West J Med 1995, 163(6):577-578.
11. Murray R.M.L., Grill V., Crinis N., et al. Hypocalcemic and normocalcemic hyperparathyroidism in patients with advanced prostate cancer. J Clin Endocrinol Metab 2001, 86(9):4133-4138.
12. Plotkin L., Weinstein R., Parfitt M., Roberson P., Manolagas S., Bellido T. Prevention of osteocyte and osteoblast apoptosis bisphosphonates and calcitionin. J Clin Invest 1999, 104:1363-1374.
13. Im G., Qureshi S., Kenney J., Rubash H., Shanbhag A. Osteoblast proliferation and maturation by bisphosphonates. Biomaterials 2004, 25:4105-4115.
14. Koch F.P., Sareh Said Yekta, Christina Merkel, Thomas Ziebart, Ralf Smeets The impact of bisphosphonates on the osteoblast proliferation and collagen gene expression in vitro. Head Face Med 2010, 6(12):1-6.
15. Reinholz G., Barbara Getz, Larry Pederson Bisphosphonates and directly regulate cell proliferation differentiation and gene expression in human osteoblasts. Cancer Res 2000, 60:6001-6007.
16. Corey E., Brown L.G., Quinn J.E. Zoledronic acid exhibits inhibitory effects on osteoblastic and osteolytic metastases of prostate cancer. Clin Cancer Res 2003, 9:295-306.
17. Lee Y.P., Schwarz E.D., Davies M., Jo M., Gates J., Zhang X., et al. Use of zoledronate to treat osteoblastic versus osteolytic lesions in a severe combined immunodeficient mouse model. Cancer Res 2002, 62:5564-5570.
18. Smith M.R., Eastham J., Gleason D., Shasha D., Tchekmedyian S., Zinner N. Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer. J Urol 2003, 169:2008-2012.
19. Ryan C., Huo D., Demers L., Beer T., Lacerna L. Zoledronic acid initiated during the first year of androgen deprivation therapy increases bone mineral density in patients with prostate cancer. J Urol 2005, 176:972-978.